Vivos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Vivos Therapeutics, Inc. (VVOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.38 per share for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-08-14
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $2.61, a 47.80% decline year-over-year.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $5.00.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $9.89, a 60.83% decline from fiscal 2022.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $25.25, a 382.79% increase from fiscal 2021.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $5.23, a 8.06% increase from fiscal 2020.
- Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $4.84.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $2.38 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | $9.89 10-K/A · filed 2024-07-30 | ||||
| 2023-09-30 | $10.00 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $0.41 10-Q · filed 2023-08-16 | ||||
| 2022-12-31 | $25.25 10-K/A · filed 2024-07-30 | $1.01 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $1.45 10-Q · filed 2022-12-20 | ||||
| 2022-06-30 | $1.29 10-Q · filed 2022-12-20 | ||||
| 2022-03-31 | $2.61 10-Q/A · filed 2022-11-25 | ||||
| 2021-12-31 | $5.23 10-K · filed 2023-03-30 | $4.96 10-K · filed 2022-03-31 | |||
| 2021-03-31 | $5.00 10-Q/A · filed 2022-11-25 | ||||
| 2020-12-31 | $4.84 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |